Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/371 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME01300311
PMID: | 1300311
LR: | 20051116
CED: | 19930521
DCO: | 19930521
Autoren: | Setnikar I
Titel: | Antireactive properties of "chondroprotective" drugs.
Quelle: | International journal of tissue reactions; VOL: 14 (5); p. 253-61 /1992/
PM: | Print
SU: | IM
Sprache: | English
CY: | SWITZERLAND
JID: | 8302116
ISSN: | 0250-0868
CO: | IJTED
Institution: | Rotta Research Laboratorium S.p.A., Monza, Italy.
DT: | Journal Article; Review
RN: | 23
Schlagwörter
CT: | ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/pharmacology; CARTILAGE, ARTICULAR/*drug effects; GLUCOSAMINE/pharmacology; GLYCOSAMINOGLYCANS/pharmacology; OSTEOARTHRITIS/*drug therapy; S-ADENOSYLMETHIONINE/analogs & derivatives; S-ADENOSYLMETHIONINE/pharmacology
CTG: | TIER; ANTIPHLOGISTIKA, NICHTSTEROIDALE/Pharmakologie; KNORPEL, GELENK-/*Arzneimittelwirkungen; GLUCOSAMIN/Pharmakologie; GLYCOSAMINO-GLYCANE/Pharmakologie; OSTEOARTHROSE/*Arzneimitteltherapie; S-ADENOSYLMETHIONIN/Analoge & Derivate; S-ADENOSYLMETHIONIN/Pharmakologie
TE: | Anti-Inflammatory Agents, Non-Steroidal; Glycosaminoglycans; galactosamine glucuronoglycan sulfate; S-Adenosylmethionine/29908-03-0; Glucosamine/3416-24-8; adenosylmethionine tosylate bis(sulfate)/97540-22-2
CR: | 29908-03-0; 3416-24-8; 97540-22-2
AB: | The medicinal therapy of osteoarthritis is based on the use of analgesics, NSAIDs and corticosteroids to relieve pain and inflammation. In addition, "chondroprotective" agents (CPA) are used to stop the evolution of the disease. In this review the biochemical and pharmacological activities of some of the most widely used CPAs are described. All of these show more or less marked antiinflammatory activities, which for some of them are the result of an inhibition of cyclo-oxygenase and of prostaglandin biosynthesis, in which case they should be more properly classified as mild NSAIDs. Only two of the CPAs reviewed, diacerein and D-glucosamine sulfate, elicit antiinflammatory and antireactive effects without significant inhibition of the prostaglandin biosynthesis. These agents have also remarkable chondroprotective effects, and only these two agents should be classified as true CPAs. In particular glucosamine sulfate, which naturally occurs in the human body and is almost devoid of toxicity, is suitable for long-term therapeutic use. This, with its chondrometabolic, antireactive and antiarthritic properties, represents the pharmacological rationale for the use of glucosamine sulfate as a disease-modifying agent in osteoarthritis.

» Volltext »
» Fenster schließen »